Growth Transformation of B Cells by Epstein-Barr Virus Requires IMPDH2 Induction and Nucleolar Hypertrophy

EBV infections cause nucleolar enlargement via the induction of IMPDH2, which are essential for B cell growth transformation by EBV. Although the significance of IMPDH2 induction and nuclear hypertrophy in the tumorigenesis of glioblastoma has been reported, EBV infection brings about the change quickly by using its transcriptional cofactor, EBNA2, and MYC. Moreover, we present here, for the novel, basic evidence that an IMPDH2 inhibitor, namely, MPA or MMF, can be used for EBV-positive posttransplant lymphoproliferative disorder (PTLD). ABSTRACT The in vitro growth transformation of primary B cells by Epstein-Barr virus (EBV) is the initial step in the development of posttransplant lymphoproliferative disorder (PTLD). We performed electron microscopic analysis and immunostaining of primary B cells infected with wild-type EBV. Interestingly, the nucleolar size was increased by two days after infection. A recent study found that nucleolar hypertrophy, which is caused by the induction of the IMPDH2 gene, is required for the efficient promotion of growth in cancers. In the present study, RNA-seq revealed that the IMPDH2 gene was significantly induced by EBV and that its level peaked at day 2. Even without EBV infection, the activation of primary B cells by the CD40 ligand and interleukin-4 increased IMPDH2 expression and nucleolar hypertrophy. Using EBNA2 or LMP1 knockout viruses, we found that EBNA2 and MYC, but not LMP1, induced the IMPDH2 gene during primary infections. IMPDH2 inhibition by mycophenolic acid (MPA) blocked the growth transformation of primary B cells by EBV, leading to smaller nucleoli, nuclei, and cells. Mycophenolate mofetil (MMF), which is a prodrug of MPA that is approved for use as an immunosuppressant, was tested in a mouse xenograft model. Oral MMF significantly improved the survival of mice and reduced splenomegaly. Taken together, these results indicate that EBV induces IMPDH2 expression through EBNA2-dependent and MYC-dependent mechanisms, leading to the hypertrophy of the nucleoli, nuclei, and cells as well as efficient cell proliferation. Our results provide basic evidence that IMPDH2 induction and nucleolar enlargement are crucial for B cell transformation by EBV. In addition, the use of MMF suppresses PTLD. IMPORTANCE EBV infections cause nucleolar enlargement via the induction of IMPDH2, which are essential for B cell growth transformation by EBV. Although the significance of IMPDH2 induction and nuclear hypertrophy in the tumorigenesis of glioblastoma has been reported, EBV infection brings about the change quickly by using its transcriptional cofactor, EBNA2, and MYC. Moreover, we present here, for the novel, basic evidence that an IMPDH2 inhibitor, namely, MPA or MMF, can be used for EBV-positive posttransplant lymphoproliferative disorder (PTLD).

[1]  T. Murata,et al.  Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation , 2021, Viruses.

[2]  M. Uddin,et al.  A STING inhibitor suppresses EBV‐induced B cell transformation and lymphomagenesis , 2021, Cancer science.

[3]  H. Trottier,et al.  Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants , 2021, Pediatric transplantation.

[4]  T. Kanda,et al.  RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. , 2021, Virology.

[5]  Y. Okuno,et al.  Role of Epstein–Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma , 2021, Cancers.

[6]  Bo Zhao,et al.  Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival , 2021, bioRxiv.

[7]  B. Sugden,et al.  Epstein–Barr Virus: How Its Lytic Phase Contributes to Oncogenesis , 2020, Microorganisms.

[8]  N. Koonrungsesomboon,et al.  Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. , 2020, European journal of pharmacology.

[9]  A. Sasaki,et al.  GTP Metabolic Reprogramming by IMPDH2: Unlocking Cancer Cells' Fueling Mechanism. , 2020, Journal of biochemistry.

[10]  H. Katoh,et al.  Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2 , 2020, Microbiology and immunology.

[11]  John G Doench,et al.  DNA Methylation Enzymes and PRC1 Restrict B-cell Epstein-Barr Virus Oncoprotein Expression , 2020, Nature Microbiology.

[12]  John G Doench,et al.  MYC Controls the Epstein-Barr Virus Lytic Switch. , 2020, Molecular cell.

[13]  Y. Okuno,et al.  Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection , 2020, bioRxiv.

[14]  Yuan Tian,et al.  The expression and prognostic role of IMPDH2 in ovarian cancer. , 2020, Annals of diagnostic pathology.

[15]  Atique U. Ahmed,et al.  De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma , 2020, bioRxiv.

[16]  J. C. de la Torre,et al.  Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses , 2020, Journal of Virology.

[17]  J. Gall The human nucleolus organizer regions , 2019, Genes & development.

[18]  Masahiro Yoshida,et al.  Antitumor activity of cyclin‐dependent kinase inhibitor alsterpaullone in Epstein‐Barr virus‐associated lymphoproliferative disorders , 2019, Cancer science.

[19]  Eric P. Smith,et al.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story , 2019, Cancers.

[20]  M. Weekes,et al.  Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival , 2019, PLoS pathogens.

[21]  A. Rickinson,et al.  The Global Landscape of EBV-Associated Tumors , 2019, Front. Oncol..

[22]  R. Deberardinis,et al.  IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma , 2019, Nature Cell Biology.

[23]  W. Hammerschmidt,et al.  The first days in the life of naïve human B-lymphocytes infected with Epstein-Barr virus , 2019, bioRxiv.

[24]  Mingxiang Teng,et al.  RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes , 2019, Journal of Virology.

[25]  M. Morton,et al.  A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature , 2019, Oncotarget.

[26]  A. Scialdone,et al.  Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection , 2018, Proceedings of the National Academy of Sciences.

[27]  P. Wieczorek,et al.  Inosine monophosphate dehydrogenase 2 as a marker of aggressive and advanced prostate cancer , 2018, Central European journal of urology.

[28]  R. Deberardinis,et al.  Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.

[29]  Jiaxing Zhang,et al.  Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma. , 2018, American journal of cancer research.

[30]  Bo Zhao,et al.  Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300 , 2018, Journal of Virology.

[31]  E. Kieff,et al.  The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. , 2017, Cell host & microbe.

[32]  R. Scott Epstein-Barr virus: a master epigenetic manipulator. , 2017, Current opinion in virology.

[33]  M. West Chromatin reorganisation in Epstein-Barr virus-infected cells and its role in cancer development. , 2017, Current opinion in virology.

[34]  M. Koopmans,et al.  Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication , 2017, Antimicrobial Agents and Chemotherapy.

[35]  Deepali Kumar,et al.  Clinical and virologic outcomes in high‐risk adult Epstein‐Barr virus mismatched organ transplant recipients , 2017, Clinical transplantation.

[36]  John G Doench,et al.  CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. , 2017, Cell host & microbe.

[37]  Jiaxing Zhang,et al.  High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma , 2017, Scientific Reports.

[38]  E. Kieff,et al.  Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation , 2016, Proceedings of the National Academy of Sciences.

[39]  M. Koopmans,et al.  Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. , 2016, Antiviral research.

[40]  M. Oren,et al.  The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. , 2016, Seminars in cancer biology.

[41]  J. Rathmell,et al.  Metabolic stress is a barrier to Epstein–Barr virus-mediated B-cell immortalization , 2016, Proceedings of the National Academy of Sciences.

[42]  P. Burger,et al.  Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage , 2015, Oncotarget.

[43]  M. Luftig,et al.  To Be or Not IIb: A Multi-Step Process for Epstein-Barr Virus Latency Establishment and Consequences for B Cell Tumorigenesis , 2015, PLoS pathogens.

[44]  E. Kieff,et al.  Epstein-Barr virus oncoprotein super-enhancers control B cell growth. , 2015, Cell host & microbe.

[45]  E. Kieff,et al.  Epstein–Barr virus latent genes , 2015, Experimental & Molecular Medicine.

[46]  Y.G. Li,et al.  IMPDH2 mediate radioresistance and chemoresistance in osteosarcoma cells. , 2014, European review for medical and pharmacological sciences.

[47]  R. Pearson,et al.  Targeting the nucleolus for cancer intervention. , 2014, Biochimica et biophysica acta.

[48]  D. Xia,et al.  Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer , 2014, Clinical and Translational Oncology.

[49]  A. Feinberg,et al.  Large-scale hypomethylated blocks associated with Epstein-Barr virus–induced B-cell immortalization , 2014, Genome research.

[50]  Fatima Al-Shahrour,et al.  The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion , 2013, Genome Biology.

[51]  M. Fraga,et al.  The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion , 2013, Genome Biology.

[52]  J. Kwekkeboom,et al.  Mycophenolic acid augments interferon‐stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo , 2012, Hepatology.

[53]  D. Abramowicz,et al.  Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  I. Hutchinson,et al.  Association of Immunosuppressive Maintenance Regimens With Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients , 2012, Transplantation.

[55]  M. Klinger,et al.  Malignancy after renal transplantation in the new era of immunosuppression. , 2011, Annals of transplantation.

[56]  Robert E. White,et al.  An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells , 2010, Cell host & microbe.

[57]  J. Fellenberg,et al.  Overexpression of Inosine 5′-Monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells , 2010, PloS one.

[58]  W. Hammerschmidt,et al.  Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of Primary Human B Cells , 2010, PLoS pathogens.

[59]  T. Kanda,et al.  Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. , 2009, The Journal of general virology.

[60]  B. Chaigne-Delalande,et al.  The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal1 , 2008, The Journal of Immunology.

[61]  A. Makhlough,et al.  Posttransplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience. , 2008, Iranian journal of kidney diseases.

[62]  L. Montanaro,et al.  Nucleolus, ribosomes, and cancer. , 2008, The American journal of pathology.

[63]  K. Zeller,et al.  Global Regulation of Nucleotide Biosynthetic Genes by c-Myc , 2008, PloS one.

[64]  D. Zhuang,et al.  Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells , 2008, Cell cycle.

[65]  L. Young,et al.  EBV gene expression and regulation , 2007 .

[66]  R. Moss‐Morris,et al.  Epstein-Barr virus infection , 2007 .

[67]  F. Boisvert,et al.  The multifunctional nucleolus , 2007, Nature Reviews Molecular Cell Biology.

[68]  Elliott Kieff,et al.  RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Walker,et al.  Posttransplant Lymphoproliferative Disorder among Renal Transplant Patients in Relation to the Use of Mycophenolate Mofetil , 2005, Transplantation.

[70]  W. Hammerschmidt,et al.  Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.

[71]  S. Peñuelas,et al.  Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells , 2005, The FEBS journal.

[72]  A. Allison Mechanisms of action of mycophenolate mofetil , 2005, Lupus.

[73]  J. Shaughnessy,et al.  Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients , 2004, Clinical Cancer Research.

[74]  M. O. Moraes,et al.  Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. , 2004, Transplantation proceedings.

[75]  E. De Clercq,et al.  Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice , 2003, BMC Microbiology.

[76]  S. Hamilton-Dutoit,et al.  Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? , 2003, Transplantation.

[77]  M. Diamond,et al.  Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. , 2002, Virology.

[78]  D. Stablein,et al.  Mycophenolate, tacrolimus and post‐transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study , 2002, Pediatric transplantation.

[79]  D. Margolis,et al.  Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. , 2002, Antiviral research.

[80]  L. Strobl,et al.  EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. , 2001, Seminars in cancer biology.

[81]  M. Melamed,et al.  Morphometry of nucleoli and expression of nucleolin analyzed by laser scanning cytometry in mitogenically stimulated lymphocytes. , 2001, Cytometry.

[82]  J. Lerut,et al.  USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION , 2001, Transplantation.

[83]  S. Hamilton-Dutoit,et al.  Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. , 1999, Transplantation.

[84]  E. De Clercq,et al.  Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro , 1999, Journal of viral hepatitis.

[85]  B. Kempkes,et al.  The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.

[86]  L. Shaw,et al.  Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. , 1998, Transplantation.

[87]  L. Shaw,et al.  Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. , 1995, Clinical chemistry.

[88]  A. Allison,et al.  Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. , 1994, Transplantation proceedings.

[89]  E. Kieff,et al.  Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes , 1994, Antimicrobial Agents and Chemotherapy.

[90]  Liang Zhou,et al.  Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer , 2014, Medical Oncology.

[91]  M. Parida,et al.  Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. , 2011, Antiviral research.

[92]  R. Hetzer,et al.  Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.